View Older Stories View More Recent Stories

Jan 5, 2022 07:00AM Biohaven and Pfizer Complete Collaboration Transaction for Commercialization of Rimegepant and Zavegepant Outside United States
Jan 5, 2022 06:45AM Pfizer (PFE) and BioNTech (BNTX) Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Jan 5, 2022 06:45AM Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Jan 5, 2022 06:45AM Pfizer and BioNTech Sign New Global Collaboration Agreement to Develop First mRNA-based Shingles Vaccine
Jan 4, 2022 03:10PM Pfizer to supply U.S. with 10 million more courses of COVID-19 pills
Jan 4, 2022 11:48AM Pfizer (PFE) Says U.S. to Purchase an Additional 10 Million Courses of PAXLOVID
Jan 4, 2022 11:45AM Pfizer to Provide U.S. Government with an Additional 10 Million Treatment Courses of its Oral Therapy to Help Combat COVID-19
Jan 4, 2022 10:00AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Jan 3, 2022 09:50AM Pfizer (PFE), BioNTech (BNTX) Confirm U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
Jan 3, 2022 09:45AM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 12 Years of Age and Older
Dec 30, 2021 10:00AM Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Dec 28, 2021 10:00AM Pfizer Invites Public to View and Listen to Webcast of February 8 Conference Call with Analysts
Dec 22, 2021 12:22PM Pfizer (PFE) Announces U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Dec 22, 2021 12:19PM Pfizer Receives U.S. FDA Emergency Use Authorization for Novel COVID-19 Oral Antiviral Treatment
Dec 22, 2021 05:48AM Pfizer (PFE) Announces Additional Order for 2.5M Courses of Oral Antiviral COVID-19 Candidate from the UK Government
Dec 22, 2021 02:53AM Pfizer to Provide the United Kingdom an Additional 2.5 Million Treatment Courses of Investigational Oral Antiviral Candidate to Help Combat COVID-19
Dec 20, 2021 04:32PM Pfizer's (PFE) VYNDAQEL/VYNDAMAX Reduced Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
Dec 20, 2021 04:30PM Pfizer’s VYNDAQEL®/VYNDAMAX® Reduced the Risk of All-Cause Mortality by 41% Among Patients with Transthyretin Amyloid Cardiomyopathy, Five-Year Follow-Up Data Demonstrate
Dec 20, 2021 10:05AM Pfizer and BioNTech to Provide European Union More Than 200 Million Additional Doses of COMIRNATY® to Help Meet Continued Need for Vaccine Supply
Dec 17, 2021 02:22PM 'Tidal wave': Omicron could put U.S. COVID-19 surge into overdrive
Dec 16, 2021 10:30AM EMA Issues Advice for Potential Early Use of Pfizer’s Novel COVID-19 Oral Antiviral Candidate
Dec 14, 2021 04:08PM Pfizer (PFE) Announces FDA Approval of XELJANZ for the Treatment of Active Ankylosing Spondylitis
Dec 14, 2021 04:08PM U.S. FDA Approves Pfizer’s XELJANZ® (tofacitinib) for the Treatment of Active Ankylosing Spondylitis
Dec 14, 2021 06:48AM Pfizer (PFE) says antiviral for covid significantly reduced risk of hospitalization or death
Dec 14, 2021 06:45AM Pfizer Announces Additional Phase 2/3 Study Results Confirming Robust Efficacy of Novel COVID-19 Oral Antiviral Treatment Candidate in Reducing Risk of Hospitalization or Death
Dec 13, 2021 06:45AM Pfizer to Acquire Arena Pharmaceuticals
Dec 13, 2021 05:04AM Sangamo Therapeutics (SGMO) and Pfizer (PFE) Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Dec 12, 2021 04:30PM Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Bleeding Control in Highest Dose Cohort Through Two Years Following Hemophilia A Gene Therapy
Dec 10, 2021 12:00PM Pfizer Declares First-Quarter 2022 Dividend
Dec 10, 2021 09:27AM Pfizer's (PFE) Cibinqo Approved in EU for Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Dec 10, 2021 09:27AM European Commission Approves Pfizer’s Cibinqo® (abrocitinib) for the Treatment of Adults with Moderate-to-Severe Atopic Dermatitis
Dec 10, 2021 08:12AM Arvinas Inc. (ARVN) and Pfizer (PFE) Announce PROTAC Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breas
Dec 10, 2021 08:10AM Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Dec 10, 2021 08:10AM Arvinas and Pfizer Announce PROTAC® Protein Degrader ARV-471 Continues to Demonstrate Encouraging Clinical Benefit Rate in Patients with Locally Advanced or Metastatic ER+/HER2- Breast Cancer
Dec 9, 2021 12:15PM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Dec 9, 2021 12:07PM Pfizer (PFE), BioNTech (BNTX) Confirm U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Dec 9, 2021 12:07PM Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization of COVID-19 Vaccine Booster for Individuals 16 Years and Older
Dec 8, 2021 06:56AM Pfizer and BioNTech Provide Update on Omicron Variant
Dec 8, 2021 06:55AM Pfizer (PFE) and BioNtech (BNTX) Announces Study Shows Omicron Variant is Neutralized by Their COVID-19 Vaccine With Three Doses
Dec 8, 2021 06:54AM Pfizer and BioNTech Provide Update on Omicron Variant
Dec 7, 2021 04:11PM Studies suggest Pfizer shot may protect only partially against Omicron
Dec 7, 2021 10:00AM Pfizer Invites Public to Register for Webcast of Analyst and Investor Call to Discuss Pfizer-BioNTech COVID-19 Vaccine and Pfizer’s Novel COVID-19 Oral Antiviral Treatment Candidate
Nov 30, 2021 07:01PM Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing Discrimination
Nov 24, 2021 10:00AM Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
Nov 24, 2021 06:31AM Ionis Pharmaceuticals (IONS) Report Positive Topline Results from Pfizer's (PFE) Phase 2b Study of Vupanorsen
Nov 22, 2021 06:46AM Pfizer (PFE), BioNTech (BNTX) Follow-Up Data From Phase 3 Trial of COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Nov 22, 2021 06:46AM BioNTech SE (BNTX) and Pfizer (PFE) Vaccine 100% Effectice Against COVID-19 in 12-15 Age Group per Phase 3 Study
Nov 22, 2021 06:45AM Follow-Up Data from Phase 3 Trial Of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Nov 22, 2021 06:45AM Follow-Up Data From Phase 3 Trial of Pfizer-BioNTech COVID-19 Vaccine Support Safety and High Efficacy in Adolescents 12 Through 15 Years of Age
Nov 19, 2021 09:56AM Arvinas Inc. (ARVN), Pfizer (PFE) Announce Updated Phase 1 Dose Escalation Data for ARV-471 to be Presented in Spotlight Poster Session at 2021 San Antonio Breast Cancer Symposium
View More Recent Stories View Older Stories